Two ‘Step-Changing’ Drugs For Waldenström’s Macroglobulinemia Fail To Win English Funding
NICE has issued final guidance for Imbruvica and preliminary guidance for Brukinsa, saying that while clinical evidence supports using the BTK inhibitors for WM, it is not convinced that either drug will be a cost-effective use of National Health Service resources.
You may also be interested in...
English Funding Rejections Reversed For Brukinsa, Adtralza, Cibinqo & Rinvoq
Health technology assessment institute NICE now believes that BeiGene’s drug for Waldenström's macroglobulinemia and three atopic dermatitis treatments, from LEO, Pfizer and AbbVie, are cost-effective.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add a new product – Tibsovo, Servier’s treatment for IDH1-mutated acute myeloid leukemia and IDH1-mutated cholangiocarcinoma.
Europe's Unitary Patent System Starts Up Today
The forthcoming unitary patent system and Unified Patent Court promise to make applying for patents in Europe and litigating infringements simpler and less costly for applicants.